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Abstract:
Background:
Antibodies to salivary gland protein 1 (SP1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP) were discovered in an
animal model of Sjogren’s syndrome (SS). Their expression was noted in patients with SS, especially those with lower focus scores
on lip biopsies and those with early disease lacking antibodies to Ro and La.
Objective:
The current studies evaluated these autoantibodies in patients with long-standing SS expressing high levels of anti-Ro antibodies and
in  patients  with  Sjogren’s  syndrome  secondary  to  systemic  lupus  erythematosus  (SLE),  systemic  sclerosis  (SSc)  and  mixed
connective tissue disease (MCTD).
Method:
Sera were obtained from patients and evaluated by ELISA for IgG, IgA and IgM antibodies to SP1, CA6 and PSP.
Results:
IgA anti-CA6 antibodies were noted in 38% of these patients, but anti-SP1, CA6 and PSP IgM or IgG antibodies were identified only
in a minority of patients. In patients with secondary SS, antibodies to SP1/CA6/PSP were more sensitive and specific than anti-Ro .
Conclusions:
While  more  studies  are  needed,  antibodies  to  SP1,  CA6  and  PSP  provide  valuable  markers  for  the  diagnosis  of  primary  and
secondary SS, especially early in the course of the disease.
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INTRODUCTION
Sjogren’s syndrome (SS) is a common autoimmune disease in which damage to the salivary and lacrimal glands
leads to dry eyes and dry mouth and secondary problems from the lack of protective secretions. A percentage of patients
with  primary  SS  will  also  develop  systemic  manifestations  including  lung  disease,  kidney  disease,  peripheral
neuropathy,  vasculitis  and lymphoma [1,  2].  SS may also occur  secondary to other  autoimmune diseases including
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis (PM) and mixed
connective tissue disease (MCTD) [3, 4].
Diagnostic criteria for SS are frequently being re-evaluated as more is learned about the pathophysiology of the
disorder and markers that readily identify it. Both European and American criteria for the diagnosis of SS include anti-
Ro antibodies [5]. More recently, additional antibodies recognizing specific salivary gland and lacrimal gland tissues
have  been  identified  in  SS,  anti-salivary  gland  protein  1  (SP1),  anti-carbonic  anhydrase  6  (CA6)  and  anti-parotid
secretory protein (PSP) [6 - 8]. Studies in animal models of SS demonstrate that these autoantibodies are expressed
earlier in the course of the disease than anti-Ro and anti-La [6]. Human studies completed to date have shown that these
autoantibodies occur in patients with lower focus scores on minor salivary gland biopsies than patients expressing anti-
Ro,  in  patients  with  SS  secondary  to  rheumatoid  arthritis  and  in  30-45% of  patients  with  SS  identified  by  clinical
criteria who lack anti-Ro antibodies [7, 8]. The current studies were undertaken to evaluate anti-SP1, anti-CA6 and anti-
PSP in a Belgian population of patients with primary and secondary SS. All primary SS were identified by clinical
criteria and the presence of anti-Ro antibodies. Patients with secondary SS met clinical criteria with or without anti-Ro
antibodies.
MATERIALS AND METHODS
Patients
Patient sera were obtained from a population of patients with autoimmune diseases followed at the department of
Rheumatology in the University Hospital of Leuven, Belgium. Accepted European Criteria were used for the diagnosis
of SS, SLE, SSc, PM and MCTD [9 - 13]. The treating physicians identified the presence of clinical symptoms and
signs consistent with SS. Patients with primary SS were routinely followed up in the clinical department and questioned
about the presence of sicca symptoms at every routine visit. Patients that were diagnosed with SLE, SSc, PM or MCTD
were sent  a  questionnaire assessing sicca symptoms and medication use both at  the time of serum sampling and at
present.  The  local  Ethical  committee  approved  the  clinical  studies.  The  patients  included  in  the  studies  were:  1)
Sjogren’s 3 male and 34 female, ages 25-87 years (mean 63 years), 2) SLE 1 male and 16 females, ages 38 – 73 years
(mean 52 years); 3) SSc 3 males and 11 females ages 45 – 77 years (mean 63 years); 4) MCTD 2 males and 9 females
ages 27 – 72 years (mean 58 years). Normal controls were obtained from the Buffalo, New York (USA) area under a
protocol approved by the Institutional Review Board SUNY at Buffalo School of Medicine. There were 24 females and
18 males ages 19 – 58 (mean 34 years).
Serological Testing
Autoantibodies to SP1, PSP, CA-VI, Ro and La were determined using ImmuLisa ELISAs (Immco Diagnostics
Inc., Buffalo, NY). In brief, kits contain micro-wells coated with highly purified recombinant antigen (SP1 or PSP or
CA-VI or Ro or La) or native antigens (RF). 96 plate wells are blocked and stabilized by the manufacturer to reduce
non-specific binding. Controls, calibrators and diluted (1:100) patient serum are incubated in the antigen-coated wells to
allow  specific  binding  of  autoantibodies  to  the  antigen.  Unbound  serum  components  are  washed  off  and  bound
antibodies  are  detected  after  incubations  with  anti-human  IgG  conjugated  to  HRP  (Horse  Radish  Peroxidase)  and
specific  enzyme  substrate  (TMB)  as  per  manufacturer’  s  protocol.  The  chromogenic  reaction  is  stopped  and  the
intensity  of  the  color  change,  which  is  proportional  to  the  concentration  of  the  bound  autoantibody,  is  read  by  a
spectrophotometer at 450 nm. Results are expressed in ELISA units per milliliter (EU/ml) using the calibrators provided
in the kit and reported as positive for a value > 20 or negative for a value < 20.
Statistical Analysis
Statistical analysis was performed using Prism version 7.00 for Macintosh (GraphPad Software, La Jolla California
USA) and unpaired student’s t tests.
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RESULTS
Studies evaluating anti-SP1, anti-CA6 and anti-PSP to date have documented their expression in some patients with
long-standing SS with or without anti-Ro or anti-La antibodies, but more commonly in patients with early or less severe
disease [6 - 8, 14]. In fact, the data to date suggest that these autoantibodies may disappear as the disease progresses
while anti-Ro and anti-La become more prominent. The ELISA assays done in the studies evaluated only IgM and IgG
autoantibodies.  In  the  current  studies  we  had  several  goals,  first  to  evaluate  anti-SP1,  anti-CA6  and  anti-PSP  in  a
different population of patients with advanced SS, second to see if IgA antibodies to these autoantigens were present in
long-standing / severe disease and third to see if these autoantibodies could identify patients with other autoimmune
disease and secondary SS. Previous studies in patients with rheumatoid arthritis demonstrated the ability of anti-SP1 to
identify patients with secondary SS with high specificity and sensitivity [7]. In the current studies we evaluated patients
with SLE, SSc and MCTD with or without secondary SS.
1. Presence of IgA Antibodies Directed Against SP1, CA6 and PSP in pSS Patients
We  evaluated  a  population  of  37  patients  with  long-standing  SS  and  high  titers  of  anti-Ro  antibodies.  It  was
anticipated that many of these patients would lack IgM or IgG anti-SP1, anti-CA6 or anti-PSP because of their long-
standing disease, but we had never evaluated IgA autoantibodies in this type of patient population. Fig. (1) demonstrates
as  expected  that  few if  any  of  the  patients  had  IgM or  IgG anti-SP1,  anti-CA6 or  anti-PSP.  However,  38% of  the
patients had IgA anti-CA6 antibodies while 7% had IgA anti-PSP antibodies and 9% had IgA anti-SP1 antibodies. In a
population of 42 normal controls, all patients were negative for antibodies to SP1, CA6 and PSP except one had an IgG
anti-SP1, one had an IgA anti-SP1, one had an IgM anti-PSP and one had an IgM anti-CA6. The expression of IgA anti-
CA6 in the SS patients was highly significant (p <0.001) compared to the normal controls, while the expression of the
other autoantibodies was not significantly different.
Fig. (1). Expressions of IgM, IgG and IgA anti-CA6, anti-PSP and anti-SP1 antibodies were evaluated in 42 patients with long-
standing Sjogren’s syndrome, all of who expressed anti-Ro antibodies. Data shown are the percentage of patients expressing each of
these antibodies.
2. Antibodies Directed Against CA6, PSP and SP1 in Patients with SLE, SSc and MCTD
The second study evaluated the presence of anti-CA6, anti-PSP and anti-SP1 antibodies of isotype IgG, IgA and
IgM compared to IgG anti-Ro in 8 patients with SLE and no SS, 9 patients with SLE and secondary SS, 7 patients with
SSc and no SS, 7 patients with SSc and secondary SS, 4 patients with MCTD and no SS and 7 patients with MCTD and
secondary SS. As shown in Fig. (2), anti-Ro antibodies as well as anti-SP1, anti-CA6 and anti-PSP antibodies were seen
in many patients with SLE, whether or not they had secondary SS. The differences between SLE and SLE with SS with
regards to either anti-Ro or anti-SP1/anti-CA6 /anti-PSP were not statistically significant. However, a few interesting
preliminary observations were made: 1) IgA anti-PSP antibodies were found only in patients with SLE and secondary
SS (4 of 9); this is statistically significant compared to the normal donors (p < .001); 2) IgM antibodies to SP1, CA6 or
PSP were found only in SLE patients who did not have secondary SS or developed it at the later time point; 3) of the
patients with SLE but not secondary SS who had SP1/CA6/PSP autoantibodies, the most common were IgG and/or IgA
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anti-CA6 (5/8);  and  4)  of  the  3  SLE patients  who denied  sicca  syndrome at  the  time  that  the  serum samples  were
obtained, but subsequently developed Sjogren’s syndrome at follow up (4-7 years), one had IgM anti-CA6 and anti-Ro,
one had IgM anti-CA6, IgA and IgG anti-SP1 and anti-Ro and one had only IgA anti-CA6,
Fig. (2). Expression of anti-Ro, anti-CA6, anti-PSP and anti-SPI antibodies were evaluated in 8 patients with SLE and no SS, 9
patients with SLE and secondary SS, 7 patients with SSc and no SS, 7 patients with SSc and secondary SS, 4 patients with MCTD
and  no  SS  and  7  patients  with  MCTD  and  secondary  SS.  Data  shown  are  the  percentage  of  patients  in  each  of  these  groups
expressing either IgM, IgG or IgA antibodies to CA6, PSP or SP1 or IgG antibodies to Ro.
In SSc, few patients in either group expressed anti-Ro. The expression of anti-SP1, anti-CA6 and anti-PSP was
noted in 71% of patients with secondary SS but only in 28% of patients without SS. The difference in expression of
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anti-SP1/anti-CA6/anti-PSP  compared  to  anti-Ro  in  the  patients  with  systemic  sclerosis  and  SS  was  statistically
significant (p = .0306) while it was not significant in the patients without secondary SS (p = .55). Interestingly, in all
patients with SSc and secondary SS, the antibodies were predominantly IgA – 2 IgA anti-SP1 and 3 IgA anti-PSP; one
patient had only IgG anti-CA6. Similarly, in MCTD anti-SP1, anti-CA6 and anti-PSP was identified in 58% of patients
with SS but in no patients with MCTD without SS. Among the 58% expressing these autoantibodies, all expressed IgA
anti-SP1, 2 also expressed IgA anti-PSP and 2 expressed also IgG anti-CA6. None expressed IgM autoantibodies. Anti-
Ro antibodies were present in 14% of MCTD patients with SS and 28% of MCTD patients without SS. None of these
differences were statistically significant, however, because of the small numbers of patients involved.
DISCUSSION
The current studies extend the understanding of expression of anti-SP1, anti-CA6 and anti-PSP in patients with
primary and secondary SS. The first studies confirmed the fact that IgM and IgG autoantibodies to these antigens are
rarely present in advanced disease. The novel finding was expression of IgA anti-CA6 antibodies in over one third of
these  patients.  At  the  same  time,  anti-SP1,  anti-CA6 and  anti-PSP were  shown to  be  potentially  good  markers  for
secondary SS in SSc and MCTD, although more patients need to be studied. Anti-Ro was less sensitive and less specific
than these markers. At the same time, neither anti-Ro nor anti-SP1/CA6/PSP was good at distinguishing SLE patients
with SS from those without.  Although,  3 patients  with SLE who initially denied sicca symptoms and subsequently
developed secondary SS, all had at least one of these markers. Furthermore, certain markers, such as IgA anti-PSP were
seen only in patients with SLE and SS while IgM autoantibodies were seen only in patients lacking symptoms of SS at
the time the blood tests were drawn.
Evaluation  of  IgA  autoantibodies  is  rarely  done  in  autoimmune  diseases,  although  it  makes  sense  that  disease
involving mucosal areas, such as the salivary and lacrimal glands would have IgA autoantibodies. The finding of IgA
anti-CA6 in advanced SS is interesting and worthy of further study. A switch from IgM autoantibodies early in the
course of the disease likely resulted in IgA autoantibodies late in the course of the disease. Patients with SLE and SS,
SSc and SS or MCTD with SS also had predominantly IgA autoantibodies. While larger numbers are needed to draw
definitive  conclusions,  however,  some  autoantibodies,  such  as  IgA  anti-PSP  were  seen  only  in  patients  with  an
autoimmune disease and secondary SS. IgA antibodies are certainly important in various autoimmune diseases. Patients
with only IgA anti-phospholipid antibodies have been shown to have the same clinical manifestations as patients with
IgG or IgM anti-phospholipid antibodies [15, 16]. It is possible, however, that IgA autoantibodies may play a different
role in disease pathogenesis in SS than IgM or IgG antibodies. There is some evidence in various autoimmune diseases,
such as SLE that IgM autoantibodies may play a protective role and participate in tissue healing rather than playing a
destructive role [17, 18]. Interestingly in our patients, IgM autoantibodies were only seen in patients who had not yet
developed symptoms of dry eyes or dry mouth, although several developed them later in the course of their disease.
These issues require further study.
The observation that anti-SP1/CA6/PSP identify secondary SS better than anti-Ro in SSc and MCTD is interesting
and possibly related to the fact that the secondary SS developed late in the course of the underlying disease and was
therefore picked up at an early stage of SS. Anti-Ro antibodies would be expected to appear later in the course of the
disease. It would be interesting to evaluate the sera of these same patients at a time point two years later than the current
studies  to  see  if  they developed anti-Ro antibodies.  The curious  observation is  the  frequent  expression of  all  these
antibodies in patients with SLE, whether or not secondary SS was identified. This could occur for many reasons. First,
the SLE patients compared to the SSc and MCTD disease patients may have more immune activation and therefore
express all autoantibodies at a higher level. Second, SLE patients tend to have more acute, severe disease manifestations
than SSC and MCTD patients and may not have focused as much on dry eyes and dry mouth because they were a minor
annoyance compared to their other problems. Finally, patients with SLE may all be predisposed to secondary SS but
only  manifest  the  clinical  symptoms  when  the  right  combination  of  insults  occurs.  It  was  interesting  that  patients
lacking sicca syndrome at the time of serum sampling but subsequently developed sicca did express one or more of the
markers and often IgM autoantibodies. To put this in perspective there is an intriguing observation regarding SLE and
SS made in an animal model. It was shown that the mechanisms by which the kidney is injured as compared to the
salivary glands and lacrimal glands may not be the same. Eliminating marginal zone B cells from the BAFF transgenic
mice getting this disorder prevents the SS but has no impact on the proliferative glomerulonephritis [19]. Perhaps a
different series of events in necessary for an SLE patient to develop SS than to develop SLE alone.
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CONCLUSION
In  summary,  these  studies  suggest  that  IgA  anti-CA6  autoantibodies  are  frequently  seen  in  patients  with  long-
standing SS. They suggest that further study is needed to understand the role as well as the usefulness of antibodies to
SP1, CA6 and PSP in diagnosis of secondary SS in SSc and MCTD. Previous studies suggest their role in the diagnosis
of  secondary  SS  in  rheumatoid  arthritis.  Further  studies  will  be  necessary  to  confirm  these  observations  in  larger
numbers of patients as well as to follow up with patients later in the course of their disease to see what has happened to
the expression of these autoantibodies.
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